NetApp Customers Say Hybrid Cloud is the Future of Enterprise IT in New Global Survey
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today revealed findings from its survey assessing the adoption of hybrid cloud strategies and operational focus areas among NetApp’s global enterprise customer base.
The survey of IT decision makers and infrastructure owners around the world found that 77 percent plan to operate their businesses in hybrid cloud environments for the foreseeable future in order to meet growing business demands for faster innovation, while optimizing operations and lowering infrastructure costs.
“Speed is the new scale. IT leaders everywhere are accelerating digital transformation efforts, requiring more agility and flexibility to stay ahead of their competition and deliver immediate business impact,” said Ronen Schwartz, General Manager and Senior Vice President, Cloud Volumes at NetApp. “Enterprises are embracing hybrid cloud models to effectively scale out IT resources to support business-critical applications and workloads – and NetApp is leading the industry in providing hybrid multi-cloud solutions to meet these organizations wherever they are.”
Highlights from NetApp’s 2021 Hybrid Cloud Enterprise Customer Adoption Survey include:
-
The Future is Hybrid Cloud: More than three-quarters of respondents said their organization plans to operate a hybrid cloud environment for the foreseeable future, while only 17 percent expect their organization to eventually migrate all IT to the cloud. Those surveyed listed the most important business benefits of hybrid cloud adoption to be:
- Faster Innovation - 26 percent
- Increased Responsiveness to Customers - 25 percent
- Increased Collaboration - 22 percent
- Key Operational Drivers for Hybrid Cloud Adoption: Respondents indicated they are looking to improve infrastructure flexibility and scale (27 percent), as hybrid cloud designs help IT teams get access to the on-demand and emerging technologies offered by public cloud while still leveraging legacy systems running reliably on-premises. Nearly a quarter (21 percent) said they needed to optimize costs, while 13 percent said they needed to improve data accessibility.
- Data Protection Remains Top Priority with Other Use Cases Gaining Traction: Data protection (including disaster recovery, backup and archiving) was the most popular hybrid cloud use case selected with 29 percent stating they are either utilizing hybrid cloud for data protection today or plan to within 24 months. However, customer respondents indicated they are also leveraging hybrid cloud for production use cases more than anticipated: 20 percent said they are currently integrating both on-premises and cloud resources to support the same workload for hybrid production, with 17 percent planning to do so within 24 months.
Innovative Organizations Continue to Succeed with NetApp Hybrid Cloud Solutions
The survey data shows that organizations all over the world are adopting a hybrid cloud strategy and relying on NetApp’s industry-leading solutions to accelerate their digital transformation and deliver business value faster.
“We needed the flexibility and agility of a hybrid cloud architecture to more effectively manage the massive amounts of data being generated daily across our global manufacturing facilities and development sites to accelerate time to insights and better inform decision making,” said Rohit Agrawal, Global Head of Hybrid Cloud at Siemens Healthineers. “NetApp’s hybrid cloud solutions help us streamline data center operations and keep costs under control, with the ability to centralize, manage, and secure the mission-critical data and applications.”
Methodology
The survey was conducted by NetApp among 79 organizations (54% AMER, 36% EMEA, 10% APAC) representing large and midsized organizations across diverse industries that have deployed or plan to deploy hybrid cloud architectures with NetApp.
Additional Resources
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005346/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Lance Berger
NetApp
lance.berger@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom